Cancer Treatment in Sweden - Costs of Drugs, Inpatient and Outpatient Care from 1985 to 1996 and Cost Effectiveness of New Drugs

References

• Stenbeck M, Rosen M, Holm L-E. Cancer survival in Sweden during three decades, 1961-1991. Acta Oncol 1995; 34: 881–891.
   Google Scholar
• The National Board of Health and Welfare [Socialstyrelsen]. Cancer Incidence in Sweden 1994. Stockholm: Centre for Epidemiology, 1997.
   Google Scholar
• The National Board of Health and Welfare [Socialstyrelsen]. Causes of death 1995 [Dodsorsaker 1995]. Stockholm: Centre for Epidemiology, 1997.
   Google Scholar
• Jacobson L, Lindgren B. What are the costs for diseases? Health care costs and productivity losses distributed by disease group in 1980 and 1991 [Vad kostar sjukdomarna? Sjukvardskostnader och produktionsbortfall fördelat pa sjuk-domsgrupper 1980 och 1991]. Stockholm: The National Board of Health and Welfare [Socialstyrelsen], 1996. In Swedish.
   Google Scholar
• LINFO. Lakemedelsinformation AB. FASS 1996. Pharmaceu-ticals in Sweden [Lakemedel i Sverige]. Stockholm: LINFO, 1996. In Swedish.
   Google Scholar
• The National Corporation of Swedish Pharmacies [Apoteksbo-laget]. Swedish drug statistics 1985; 1986; 1987; 1988; 1989; 1990 [Svensk lakemedelsstatistik 1985; 1986; 1987; 1988; 1989; 1990]. Stockholm; Apoteksbolaget, 1986; 1987; 1988; 1989; 1990; 1991. In Swedish.
   Google Scholar
• The National Corporation of Swedish Pharmacies [Apoteksbo-laget]. Swedish drug statistics 91; 92; 93; 94; 95; 96 [Svensk lakemedelsstatistik 91; 92; 93; 94; 95; 96]. Stockholm: Apoteks-bolaget, 1992; 1993; 1994; 1995; 1996; 1997. In Swedish.
   Google Scholar
• The National Board of Health and Welfare [Socialstyrelsen]. Classification of diseases 1987 [Klassifikation av sjukdomar 1987]. Stockholm: Socialstyrelsen, 1986. In Swedish.
   Google Scholar
• The Federation of County Councils [Landstingsförbundet]. Costs per patient in inpatient care 1993 [Kostnader per intagen patient 1993]. Stockholm: Landstingsförbundet, 1995. In Swedish.
   Google Scholar
• Lakemedelsstatistik AB. Medical Index Sweden (MIS). Statis-tical survey of prescriptions and diagnoses in Sweden. Stock-holm: Lakemedelsstatistik AB, 1986, 1988, 1991, 1996.
   Google Scholar
• The Federation of County Councils [Landstingsförbundet]. Statistical yearbook for county councils 1997 [Statistisk arsbok for landsting 1997]. Stockholm: Landstingsförbundet, 1996. In Swedish.
   Google Scholar
• Statistics Sweden. Statistical yearbook of Sweden 1997 [Statis-tisk arsbok 1997]. Stockholm: Statistics Sweden, 1997.
   Google Scholar
• Ballatori E, Roila F, Berto P, et al. Cost and cost effectiveness analysis of ondansetron versus metoclopramide regimens. A hospital perspective from Italy. PharmacoEconomics 1994; 5: 227–37.
   Google Scholar
• Cunningham D, Gore M, Davidson N, Miocevich M, Man-chanda M, Wells N. The real costs of emesis -An economic analysis of ondansetron vs. metoclopramide in controlling emesis in patients receiving chemotherapy for cancer. Eur J Cancer 1993; 29A: 303–6.
   Google Scholar
• Tanneberger S, Lelli G, Martoni A, Piana E, Pannuti F. The antiemetic efficacy and the cost-benefit ratio of ondansetron calculated with a new approach to health technology assessment (real cost-benefit index). J Chemother 1992; 4: 326–31.
   Google Scholar
• Zbrozek AS, Cantor SB, Cardenas MP, Hill DP. Pharmacoeco- nomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting. Am J Ho sp Pharm 1994; 51: 1555–63.
   PubMedGoogle Scholar
• Plosker GL, Milne RJ. Ondansetron. A pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy. PharmacoEconomics 1992; 2: 285–304.
   Google Scholar
• Plosker GL, Benfield P. Granisetron. A pharmacoeconomic evaluation of its use in the prophylaxis of chemotherapy-in-duced nausea and vomiting. PharmacoEconomics 1996; 9: 357–74.
   Google Scholar
• Börjeson S. Nausea and emesis in cancer chemotherapy: aspects of occurrence, assessment and treatment [dissertation]. Stock-holm: Karolinska Institute, 1998.
   Google Scholar
• Dranisaris G. Using filgrastim efficiently. PharmacoEconomics 1996; 9: 466–8.
   PubMedGoogle Scholar
• Frampton JE, Faulds D. Filgrastim. A reappraisal of pharma-coeconomic considerations in the prophylaxis and treatment of chemotherapy-induced neutropenia. PharmacoEconomics 1996; 9: 76–96.
   Google Scholar
• McQuaker IG, Hunter AE, Pacey S, Haynes AP, Iqbal A, Russell NH. Low-dose filgrastim significantly enhances neu-trophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: Evidence for clinical and economic benefit. J Clin Oncol 1997; 15: 451–7.
   PubMed Web of Science ®Google Scholar
• Stahel RA, Jost LM, Honegger H, Betts E, Goebel MEM, Nagler A. Randomized trial showing equivalent efficacy of filgrastim 5 ttg/kg/d and 10 ttg/kg/d following high-dose chemotherapy and autologous bone marrow transplantation in high-risk lymphomas. J Clin Oncol 1997; 15: 1730–5.
   PubMed Web of Science ®Google Scholar
• Ragnarson Tennvall G, Fernberg J-0. Economic evaluation of gemcitabine single agent therapy compared with standard treatment in stage IIIB and IV non-small cell lung cancer. Med Oncol. In press.
   Google Scholar
• Manegold C, Bergman B, Chemaissani A, et al. Single-agent gemcitabine versus cisplatin-etoposide: early results of a ran-domised phase II study in locally advanced or metastatic non-small-cell lung cancer. Ann Oncol 1997; 8: 525–9.
   PubMed Web of Science ®Google Scholar
• Covens A, Boucher S, Roche K, et al. Is paclitaxel and cisplatin a cost effective first-line therapy for advanced ovarian car-cinoma? Cancer 1996; 77: 2086–91.
   PubMed Web of Science ®Google Scholar
• Elit LM, Gafni A, Levine MN. Economic and policy implica-tions of adopting paclitaxel as first-line therapy for advanced ovarian cancer: an Ontario perspective. J Clin Oncol 1997; 15: 632–9.
   Google Scholar
• Messori A, Trippoli S, Becagli P, Tendi E. Pharmacoeconomic profile of paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma. Cancer 1996; 78: 2366–73.
   PubMed Web of Science ®Google Scholar
• McGuire W, Neugut Al, Arikian S, Doyle J, Dezii CM. Analysis of the cost effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer. J Clin Oncol 1997; 15: 640–5.
   Google Scholar
• McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophos-phamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Eng J Med 1996; 334: 1–6.
   PubMed Web of Science ®Google Scholar
• Varenhorst E, Carlsson P, Pedersen K. Clinical and economic considerations in the treatment of prostate cancer. Pharma-coEconomics 1994; 6: 127–41.
   PubMedGoogle Scholar
• Henriksson F, Hjortsberg C, Rehnberg C, Odegaard K. Phar-maceuticals and health care costs [Lakemedlen och sjukvardskostnaderna-Nagra utvecklingslinjer]. IHE Work-ing Paper 1997: 6. Lund: IHE, 1997. In Swedish.
   Google Scholar